Status:
COMPLETED
Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration
Lead Sponsor:
Pfizer
Conditions:
Macular Degeneration
Eligibility:
All Genders
18+ years
Brief Summary
The study will provide additional safety data for specific safety events in persons receiving intravitreal injections. The Committee for Medicinal Products for Human Use (CHMP) is interested in obtain...
Detailed Description
No comparator Patients with age-related macular degeneration
Eligibility Criteria
Inclusion
- Neovascular AMD patients who are eligible for Macugen therapy based on the approved label
Exclusion
- Active or suspected ocular or periocular infection. Known hypersensitivity to the active substance or any of its excipients.
Key Trial Info
Start Date :
August 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2012
Estimated Enrollment :
501 Patients enrolled
Trial Details
Trial ID
NCT00460408
Start Date
August 1 2006
End Date
February 1 2012
Last Update
December 11 2012
Active Locations (68)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Brussels, Belgium, 1200
2
Pfizer Investigational Site
Charleroi, Belgium, 6000
3
Pfizer Investigational Site
Ieper, Belgium, 8900
4
Pfizer Investigational Site
Lier, Belgium, 2500